BRPI0914121A2 - derivado de triazol ou sal do mesmo - Google Patents

derivado de triazol ou sal do mesmo

Info

Publication number
BRPI0914121A2
BRPI0914121A2 BRPI0914121A BRPI0914121A BRPI0914121A2 BR PI0914121 A2 BRPI0914121 A2 BR PI0914121A2 BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 A2 BRPI0914121 A2 BR PI0914121A2
Authority
BR
Brazil
Prior art keywords
salt
triazole derivative
triazole
derivative
Prior art date
Application number
BRPI0914121A
Other languages
English (en)
Inventor
Daisuke Sasuga
Hideyuki Watanabe
Hiroaki Hoshii
Hiroki Fukudome
Kayoko Mihara
Noriyuki Kawano
Ryosuke Munakata
Seiji Yoshimura
Takanori Koike
Tomoaki Kawano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0914121A2 publication Critical patent/BRPI0914121A2/pt
Publication of BRPI0914121B1 publication Critical patent/BRPI0914121B1/pt
Publication of BRPI0914121B8 publication Critical patent/BRPI0914121B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0914121A 2008-07-03 2009-07-02 derivado de triazol ou sal do mesmo BRPI0914121B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-174181 2008-07-03
JP2008174181 2008-07-03
PCT/JP2009/062081 WO2010001946A1 (ja) 2008-07-03 2009-07-02 トリアゾール誘導体またはその塩

Publications (3)

Publication Number Publication Date
BRPI0914121A2 true BRPI0914121A2 (pt) 2015-10-20
BRPI0914121B1 BRPI0914121B1 (pt) 2019-08-06
BRPI0914121B8 BRPI0914121B8 (pt) 2021-05-25

Family

ID=41466037

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914121A BRPI0914121B8 (pt) 2008-07-03 2009-07-02 derivado de triazol ou sal do mesmo

Country Status (24)

Country Link
US (1) US8377923B2 (pt)
EP (1) EP2298747B1 (pt)
JP (1) JP5494482B2 (pt)
KR (1) KR101589775B1 (pt)
CN (1) CN102076671B (pt)
AU (1) AU2009266756B2 (pt)
BR (1) BRPI0914121B8 (pt)
CA (1) CA2729408C (pt)
CY (1) CY1118501T1 (pt)
DK (1) DK2298747T3 (pt)
ES (1) ES2620657T3 (pt)
HR (1) HRP20170029T1 (pt)
HU (1) HUE031419T2 (pt)
IL (1) IL210316A (pt)
LT (1) LT2298747T (pt)
MX (1) MX2011000179A (pt)
PL (1) PL2298747T3 (pt)
PT (1) PT2298747T (pt)
RS (1) RS55664B1 (pt)
RU (1) RU2501791C2 (pt)
SI (1) SI2298747T1 (pt)
TW (1) TWI465439B (pt)
WO (1) WO2010001946A1 (pt)
ZA (1) ZA201100032B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049662A1 (de) * 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
BR112014001767A2 (pt) 2011-07-29 2017-02-14 Daiichi Sankyo Co Ltd composto, composição farmaccêutica, uso de um composto, e, método para o tratamento de uma doença
CN104135859B (zh) * 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
SI2882723T1 (sl) * 2012-08-07 2017-04-26 Basilea Pharmaceutica Ag Postopek izdelave izavukonazola ali ravukonazola
CN105037285A (zh) * 2015-07-13 2015-11-11 佛山市赛维斯医药科技有限公司 三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途
KR102616949B1 (ko) * 2017-09-14 2023-12-22 다이이찌 산쿄 가부시키가이샤 고리형 구조를 갖는 화합물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
AU2003259068B2 (en) 2002-08-09 2009-07-02 Astrazeneca Ab "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
JP2006522745A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換１，２，４−トリアゾールの薬学的使用
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
AU2005230864A1 (en) 2004-03-29 2005-10-20 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CN1993333B (zh) 2004-08-04 2012-08-01 大正制药株式会社 三唑衍生物
KR101214665B1 (ko) * 2004-09-16 2012-12-21 아스텔라스세이야쿠 가부시키가이샤 트리아졸 유도체 또는 그의 염
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
JPWO2006080533A1 (ja) 2005-01-31 2008-06-19 持田製薬株式会社 ３−アミノ−１，２，４−トリアゾール誘導体
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
US8541592B2 (en) * 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
AU2007225680A1 (en) 2006-03-16 2007-09-20 Astellas Pharma Inc. Triazole derivative or salt thereof

Also Published As

Publication number Publication date
CA2729408C (en) 2016-05-10
HRP20170029T1 (hr) 2017-03-24
SI2298747T1 (sl) 2017-08-31
EP2298747B1 (en) 2016-12-28
CN102076671A (zh) 2011-05-25
DK2298747T3 (en) 2017-02-13
LT2298747T (lt) 2017-02-10
KR101589775B1 (ko) 2016-01-28
IL210316A (en) 2014-07-31
BRPI0914121B8 (pt) 2021-05-25
EP2298747A4 (en) 2012-06-13
US20110105460A1 (en) 2011-05-05
ES2620657T3 (es) 2017-06-29
TWI465439B (zh) 2014-12-21
CY1118501T1 (el) 2017-07-12
PL2298747T3 (pl) 2017-05-31
JP5494482B2 (ja) 2014-05-14
RU2011103789A (ru) 2012-08-10
PT2298747T (pt) 2017-02-06
CN102076671B (zh) 2013-05-15
CA2729408A1 (en) 2010-01-07
IL210316A0 (en) 2011-03-31
US8377923B2 (en) 2013-02-19
ZA201100032B (en) 2012-03-28
BRPI0914121B1 (pt) 2019-08-06
RU2501791C2 (ru) 2013-12-20
WO2010001946A1 (ja) 2010-01-07
EP2298747A1 (en) 2011-03-23
AU2009266756A1 (en) 2010-01-07
AU2009266756B2 (en) 2013-07-04
RS55664B1 (sr) 2017-06-30
TW201006804A (en) 2010-02-16
MX2011000179A (es) 2011-04-05
JPWO2010001946A1 (ja) 2011-12-22
KR20110025688A (ko) 2011-03-10
HUE031419T2 (en) 2017-07-28

Similar Documents

Publication Publication Date Title
BRPI0818201A2 (pt) Composto de azolcarboxamida ou sal do mesmo
IL212186A0 (en) Fungicidal heterocyclic compounds
BRPI0816461A2 (pt) Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida
GB0813603D0 (en) Ventricular assist system
BRPI0912855A2 (pt) derivados de indazóis substituídos por fenila ou piridinila
ZA201005097B (en) Herbicidal compounds
ZA201005096B (en) Herbicidal compounds
GB0805318D0 (en) Herbicidal compounds
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
IL195278A0 (en) Triazole derivatives ii
BRPI0914121A2 (pt) derivado de triazol ou sal do mesmo
IL193741A0 (en) A triazole derivative or a salt thereof
BRPI0807004A2 (pt) Sal
HK1131128A1 (en) Triazole derivative
BRPI0821773A2 (pt) Monossebacato derivado de pirazol
ATE522523T1 (de) 1,3,5-trisubstituiertes triazolderivat
BRPI0812359A2 (pt) Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo
DK2308869T3 (da) Azolforbindelse
ATE555785T1 (de) Triazolderivate als smo-antagonisten
BRPI0821357A2 (pt) derivados de oxadiazois de triazol
BRPI0811103A2 (pt) Compostos triazol para tratamento de formação de biopelícula
GB2454967B (en) Animal trap
GB2447924B (en) An animal access system
BR112013014362A2 (pt) compostos de triazol iii
BRPI0812223A2 (pt) Realce do sal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF